IL-23R Inhibitors

IL-23R, a receptor subunit specific to the interleukin-23 (IL-23) receptor complex, plays a crucial role in regulating immune responses, particularly in the context of inflammatory and autoimmune diseases. As a member of the IL-12 cytokine family, IL-23R is involved in mediating signaling cascades that drive the differentiation and activation of T helper 17 (Th17) cells, leading to the production of pro-inflammatory cytokines such as interleukin-17 (IL-17) and interleukin-22 (IL-22). These cytokines contribute to the pathogenesis of various immune-mediated disorders, including psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.

Inhibition of IL-23R can be achieved through various mechanisms, both directly and indirectly. Direct inhibitors may target the IL-23R protein itself or its downstream signaling components, blocking receptor activation or downstream signaling events. Alternatively, indirect inhibitors may modulate signaling pathways or cellular processes upstream of IL-23R expression or activation, thereby suppressing its expression or function. These inhibitors can interfere with key signaling pathways involved in immune regulation, such as Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, nuclear factor kappa B (NF-κB) signaling, and mammalian target of rapamycin (mTOR) signaling, among others. By targeting IL-23R and its associated pathways, these inhibitors hold promise for the development of strategies aimed at mitigating immune-mediated inflammatory diseases.